HQTC(SH:688151)2024-04-26 11:34Financial Performance - The company's operating revenue for Q1 2024 was ¥121,337,392.45, a decrease of 36.75% compared to the same period last year[3] - The net profit attributable to shareholders was ¥14,146,460.31, down 17.38% year-on-year[3] - The net profit after deducting non-recurring gains and losses was -¥7,531,027.53, reflecting a significant decline of 198.33%[3] - The net cash flow from operating activities was -¥85,487,838.04, a decrease of 4.32% compared to the previous year[3] - Total operating revenue for Q1 2024 was CNY 121,337,392.45, a decrease of 36.7% compared to CNY 191,850,331.44 in Q1 2023[17] - Net profit for Q1 2024 was CNY 14,146,460.31, a decline of 17.3% from CNY 17,123,244.96 in Q1 2023[18] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.04, down from CNY 0.05 in Q1 2023[19] Cash Flow and Liquidity - The net cash flow from operating activities was -$85,487,838.04, compared to -$81,949,557.53 in the previous year, indicating a decline in operational cash flow[22] - The net increase in cash and cash equivalents was -$1,466,870,500.46, compared to -$1,155,142,168.75 in the previous year, reflecting a significant decrease in liquidity[23] - The ending balance of cash and cash equivalents was $258,634,672.00, down from $1,390,354,676.23 in the previous year[23] - Cash received from operating activities totaled $138,056,599.35, while cash paid for operating activities was $223,544,437.39, leading to a negative cash flow from operations[22] - The company reported cash received from tax refunds amounting to $4,877,257.86, which is a key component of operational cash inflow[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,990,670,797.13, a decrease of 1.21% from the previous year-end[4] - The total current assets as of March 31, 2024, amount to ¥3,631,738,369.33, a decrease from ¥3,807,389,370.64 as of December 31, 2023, representing a decline of approximately 4.6%[12] - The cash and cash equivalents decreased to ¥953,118,858.26 from ¥2,408,551,560.14, indicating a significant reduction of about 60.4%[12] - Total liabilities as of Q1 2024 amounted to CNY 806,540,149.95, down from CNY 881,385,462.89 in the previous period[15] - The total assets as of March 31, 2024, are ¥4,990,670,797.13, down from ¥5,051,645,259.93, reflecting a decrease of approximately 1.2%[13] Research and Development - R&D investment totaled ¥14,368,760.86, representing 11.84% of operating revenue, an increase of 4.95 percentage points[4] - Research and development expenses for Q1 2024 were CNY 14,368,760.86, slightly up from CNY 13,226,047.55 in Q1 2023[17] Market and Strategic Developments - The company experienced a significant decline in medical device sales due to the recovery from public health events, impacting revenue recognition[6] - The company has not reported any new product developments or technological advancements in the current quarter[11] - There are no significant market expansion or acquisition strategies mentioned in the current report[11] - The company has not provided any forward-looking guidance or performance outlook for the upcoming quarters[11] Shareholder Information - The top two shareholders are China Ordnance Equipment Group with 45.52% and Southern Industrial Asset Management with 24.83% of shares[8] Non-Recurring Gains - Non-recurring gains totaled ¥21,677,487.84, influenced by a 129.04% increase in fair value changes of structured deposits[6]